- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02984644
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (AZ11040)
maanantai 2. joulukuuta 2019 päivittänyt: The University of Texas Health Science Center at San Antonio
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)
To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
The increase in plasma glucagon conc and/or decrease in plasma insulin conc in response to glucosuria is (are) important signal(s) responsible, at least in part, for the increase in EGP, which the investigators anticipate will be derived primarily from the liver.
Insulin and glucagon are powerful regulators of HGP.
Therefore, the investigators anticipate that, at least in part, an increase in HGP secondary to the rise in plasma glucagon concentration and decrease in plasma insulin concentration in response to dapagliflozin-induced glucosuria will account for the majority of increase in EGP in both NGT and T2DM subjects.
This study will define whether the increase in plasma glucagon and/or the decrease in plasma insulin are the trigger to stimulate EGP.
Eligible subjects will receive three 5-hour measurements of endogenous glucose production (EGP), which is the biosynthesis of new glucose, with administration of study drug after a 3-hour tracer equilibration period.
Hepatic glucose production (HGP), which is the net release of glucose from the liver, will be measured for 5 hours after drug administration to allow sufficient time for a significant increase in HGP above baseline after dapagliflozin administration (10).
In study 1, HGP will be measured for 5 hours after dapagliflozin (10 mg) or placebo administration.
This is the control study.
The investigators expect to observe the "paradoxical" rise in EGP following dapagliflozin.
Study 2 will be performed under glucose clamp conditions (i.e.
maintaining the plasma glucose concentration stable at each subject's fasting level).
This study will define whether the decline in plasma glucose concentration is the trigger to stimulate EGP.
Study 3 will be performed under pancreatic clamp conditions (maintaining the plasma glucagon and insulin concentrations constant at the basal level).
This study will define whether the increase in plasma glucagon and/or the decrease in plasma insulin are the trigger to stimulate EGP.
Subjects will be randomized in a 2:1 ratio; 32 subjects will receive dapagliflozin and 16 subjects will receive placebo.
Each study will be performed on a separate day, after a 10-12 hour overnight fast within 1-2 week period.
Following studies 1-3, subjects will return for a renal (kidney) MRI-measurement to record kidney size.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
30
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Texas
-
San Antonio, Texas, Yhdysvallat, 78229
- University of Texas Health Science Center
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta - 70 vuotta (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- T2DM according to ADA criteria-HbA1C < 8.0%
- BMI = 25-35 kg/m2
- Subjects must be in good general health as determined by physical exam, medical history, blood chemistries, CBC, TSH, T4, EKG and urinanalysis
- Body weight has been stable (± 3 lbs) over the preceding three months
- Do not participate in an excessively heavy exercise program
- Taking stable dose (more than 3 months) of monotherapy or combination therapy with metformin and/or a sulfonylurea
Exclusion Criteria:
- Subjects taking drugs known to affect glucose metabolism (other than metformin and sulfonylurea) will be excluded
- Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be excluded
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Active Comparator: Dapagliflozin
32 subjects will receive dapagliflozin 10mg
|
Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
Muut nimet:
|
Placebo Comparator: Placebo
16 subjects will receive placebo
|
Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Measurement of the Change in Plasma Glucose (mg/dL): Study 1
Aikaikkuna: Baseline to 240-300 minutes
|
Change from baseline to the last hour of the study (240-300 minutes) in plasma glucose concentration
|
Baseline to 240-300 minutes
|
Change in Plasma Glucose Measurement Using a Glucose Clamp: Study 2
Aikaikkuna: Baseline to 240-300 minutes
|
Change from baseline to the last hour of the study (240-300 minutes) in plasma glucose for study 2: EGP plus glucose clamp.
The glucose clamp technique is achieved by increase plasma glucose concentration to 125 mg/dl above basal levels by a continuous infusion of glucose.
This hyperglycemic plateau is maintained by adjustment of a variable glucose infusion, based on the rate of insulin secretion and glucose metabolism.
Because the plasma glucose concentration is held constant, the glucose infusion rate is an index of insulin secretion and glucose metabolism.
The 3-3H-glucose infusion will be started at 6 AM to measure the basal rate of EGP.
After a 3 hour tracer equilibration period (at 9 AM) subjects will receive dapagliflozin (10 mg) or placebo, and the plasma glucose conc will be measured every 5 minutes for 5 hours (from 9AM to 2 PM)
|
Baseline to 240-300 minutes
|
Change in Plasma Glucose Using a Pancreatic Clamp: Study 3
Aikaikkuna: Baseline to 240-300 minutes
|
Change from Baseline to the last hour of the study (240-300 minutes) in plasma glucose using a pancreatic clamp.
In this study, EGP will be measured as described in Study 1 and plasma insulin and glucagon concentrations will be clamped at the basal level using the pancreatic clamp technique.
Plasma glucose concentration will be allowed to decrease spontaneously after dapagliflozin or placebo administration.
Somastatin will be infused with glucagon and insulin to replace basal plasma glucagon and insulin until study end.
|
Baseline to 240-300 minutes
|
Change in EGP: Study 1
Aikaikkuna: Baseline to 240-300 minutes
|
Change from baseline to the last hour of the study (240-300 minutes) in EGP
|
Baseline to 240-300 minutes
|
Change in EGP With Glucose Clamp: Study 2
Aikaikkuna: Baseline to 240-300 minutes
|
Change from baseline to the last hour of the study (240-300 minutes) in EGP using a glucose clamp.
The glucose clamp technique is achieved by increase plasma glucose concentration to 125 mg/dl above basal levels by a continuous infusion of glucose.
This hyperglycemic plateau is maintained by adjustment of a variable glucose infusion, based on the rate of insulin secretion and glucose metabolism.
Because the plasma glucose concentration is held constant, the glucose infusion rate is an index of insulin secretion and glucose metabolism.
The 3-3H-glucose infusion will be started at 6 AM to measure the basal rate of EGP.
After a 3 hour tracer equilibration period (at 9 AM) subjects will receive dapagliflozin (10 mg) or placebo, and the plasma glucose conc will be measured every 5 minutes for 5 hours (from 9AM to 2 PM)
|
Baseline to 240-300 minutes
|
Change in EGP With Pancreatic Clamp: Study 3
Aikaikkuna: Baseline to 240-300 minutes
|
Change from baseline to the last hour of the study (240-300 minutes) of EGP with a pancreatic clamp.
In this study, EGP will be measured as described in Study 1 and plasma insulin and glucagon concentrations will be clamped at the basal level using the pancreatic clamp technique.
Plasma glucose concentration will be allowed to decrease spontaneously after dapagliflozin or placebo administration.
Somastatin will be infused with glucagon and insulin to replace basal plasma glucagon and insulin until study end.VIn this study, EGP will be measured as described in Study 1 and plasma insulin and glucagon concentrations will be clamped at the basal level using the pancreatic clamp technique.
Plasma glucose concentration will be allowed to decrease spontaneously after dapagliflozin or placebo administration.
Somastatin will be infused with glucagon and insulin to replace basal plasma glucagon and insulin until study end.
|
Baseline to 240-300 minutes
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Change in Plasma Insulin Concentrations: Study 1
Aikaikkuna: Baseline to 240-300 minutes
|
Plasma insulin concentrations during measurement of EGP
|
Baseline to 240-300 minutes
|
Plasma Insulin Concentrations During Measurement of EGP Plus Glucose Clamp: Study 2
Aikaikkuna: Baseline to 240-300 minutes
|
Plasma insulin concentration is measured from baseline to the last hour of the study while using a glucose clamp.
The glucose clamp technique is achieved by increase plasma glucose concentration to 125 mg/dl above basal levels by a continuous infusion of glucose.
This hyperglycemic plateau is maintained by adjustment of a variable glucose infusion, based on the rate of insulin secretion and glucose metabolism.
Because the plasma glucose concentration is held constant, the glucose infusion rate is an index of insulin secretion and glucose metabolism.
The 3-3H-glucose infusion will be started at 6 AM to measure the basal rate of EGP.
After a 3 hour tracer equilibration period (at 9 AM) subjects will receive dapagliflozin (10 mg) or placebo, and the plasma glucose conc will be measured every 5 minutes for 5 hours (from 9AM to 2 PM)
|
Baseline to 240-300 minutes
|
Change in Plasma Insulin While Using Pancreatic Clamp: Study 3
Aikaikkuna: Baseline to last hour of the study
|
Plasma insulin concentration during measurement of EGP while using pancreatic clamp.
In this study, EGP will be measured as described in Study 1 and plasma insulin and glucagon concentrations will be clamped at the basal level using the pancreatic clamp technique.
Plasma glucose concentration will be allowed to decrease spontaneously after dapagliflozin or placebo administration.
Somastatin will be infused with glucagon and insulin to replace basal plasma glucagon and insulin until study end.
|
Baseline to last hour of the study
|
Change in Glucagon: Study 1
Aikaikkuna: Baseline to 240-300 minutes
|
Change in glucagon concentrations during measurement of EGP
|
Baseline to 240-300 minutes
|
Change in Glucagon Using Glucose Clamp: Study 2
Aikaikkuna: Baseline to 240-300 minutes
|
Plasma glucagon concentration during measurement of EGP using a glucose clamp.
The glucose clamp technique is achieved by increase plasma glucose concentration to 125 mg/dl above basal levels by a continuous infusion of glucose.
This hyperglycemic plateau is maintained by adjustment of a variable glucose infusion, based on the rate of insulin secretion and glucose metabolism.
Because the plasma glucose concentration is held constant, the glucose infusion rate is an index of insulin secretion and glucose metabolism.
|
Baseline to 240-300 minutes
|
Change in Glucagon Using Pancreatic Clamp: Study 3
Aikaikkuna: Baseline to 240-300 minutes
|
Measurement of change in plasma glucagon from baseline to one hour prior to end of study while using a pancreatic clamp.
In this study, EGP will be measured as described in Study 1 and plasma insulin and glucagon concentrations will be clamped at the basal level using the pancreatic clamp technique.
Plasma glucose concentration will be allowed to decrease spontaneously after dapagliflozin or placebo administration.
Somastatin will be infused with glucagon and insulin to replace basal plasma glucagon and insulin until study end.
|
Baseline to 240-300 minutes
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Keskiviikko 6. syyskuuta 2017
Ensisijainen valmistuminen (Todellinen)
Perjantai 16. marraskuuta 2018
Opintojen valmistuminen (Todellinen)
Lauantai 16. marraskuuta 2019
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Keskiviikko 30. marraskuuta 2016
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Perjantai 2. joulukuuta 2016
Ensimmäinen Lähetetty (Arvio)
Keskiviikko 7. joulukuuta 2016
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 18. joulukuuta 2019
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Maanantai 2. joulukuuta 2019
Viimeksi vahvistettu
Perjantai 1. marraskuuta 2019
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- HSC20160586H
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Joo
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Tyyppi II; Diabetes
-
The Second Hospital of QinhuangdaoValmisOikean säteittäispään suljettu Frykman Type II -murtuma
-
Sohag Universitysohag university hospitalRekrytointiSääriluun tasangon murtumat Schatzker Type IIEgypti
-
Ain Shams Maternity HospitalRekrytointiHuono vaste ovulaation induktioon Poseidon Type IVEgypti
-
Freeman-Sheldon Research Group, Inc.LopetettuKraniofacial poikkeavuudet | Arthrogryposis | Freeman-Sheldonin oireyhtymä | Arthrogryposis Distal Type 2A | Viheltävä kasvojen oireyhtymä | Kraniocarpotarsaalinen dysplasia | Kraniocarpotarsaalinen dystrofia | Freeman-Sheldonin oireyhtymän variantti | Sheldon-Hallin oireyhtymä | Arthrogryposis Distal Type 2B | Gordonin... ja muut ehdotYhdysvallat
-
pico-tesla Magnetic Therapies, LLCValmisTyypin II diabetes mellitusYhdysvallat
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...LopetettuTyypin II diabetes mellitusSaksa
-
HealthInsightCenter for Technology and Aging; VoxivaTuntematonTyypin II diabetes mellitusYhdysvallat
-
Khoo Teck Puat HospitalValmisTyypin II diabetes koehenkilöillä BMI 27-32Singapore
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyValmisMiespotilaat, joilla on tyypin II diabetes (T2DM)Saksa
-
Unity Health TorontoValmis